BriaCell Therapeutics Corp. (BCTX) Change in Accured Expenses (2021 - 2026)

BriaCell Therapeutics has reported Change in Accured Expenses for 6 years, with the latest figure at $110156.0 in Q2 2026.

• Quarterly Change in Accured Expenses fell 86.63% year-over-year to $110156.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $364630.0 (down 65.8% YoY) and the FY2025 annual result came in at $753909.0, up 294.64% from the prior year.
• Change in Accured Expenses eased to $110156.0 in Q2 2026 per BCTX's latest filing, from $117045.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $823830.0 in Q2 2025 and troughed at -$399720.0 in Q1 2024.
• A 5-year average of $87674.8 and a median of $89247.5 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses jumped 812.89% in 2024, then tumbled 694.02% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$295505.0 in 2022, then soared by 77.96% to -$65128.0 in 2023, then surged by 812.89% to $464292.0 in 2024, then grew by 6.52% to $494573.0 in 2025, then tumbled by 77.73% to $110156.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $110156.0, $117045.0, and $494573.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.